| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Biodesix stock rises after expanded Bio-Rad partnership | 1 | Investing.com | ||
| Mi | Biodesix to validate ESR1 mutation test for advanced breast cancer | 1 | Investing.com | ||
| Mi | Biodesix validiert ESR1-Mutationstest für fortgeschrittenen Brustkrebs | 1 | Investing.com Deutsch | ||
| Mi | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | 223 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| 15.10. | Biodesix, Inc.: Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 06.10. | Biodesix, Inc.: Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit | 1 | GlobeNewswire (USA) | ||
| 01.10. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 19.09. | Canaccord senkt Kursziel für Biodesix auf 20 US-Dollar, bestätigt aber Kaufempfehlung | 2 | Investing.com Deutsch | ||
| 19.09. | Biodesix stock price target lowered to $20 by Canaccord, maintains Buy rating | 1 | Investing.com | ||
| 11.09. | Biodesix, Inc.: Biodesix Announces One-for-Twenty Reverse Stock Split | 114 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock... ► Artikel lesen | |
| 11.09. | BIODESIX INC - 8-K, Current Report | 3 | SEC Filings | ||
| 04.09. | Biodesix Stock Surges Over 51% Overnight After Jack Schuler's $1.5M Share Purchase Revealed | 2 | Benzinga.com | ||
| 19.08. | Biodesix, Inc.: Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics | 5 | GlobeNewswire (USA) | ||
| 07.08. | Biodesix GAAP EPS of -$0.08 misses by $0.01, revenue of $20M beats by $1.53M | 2 | Seeking Alpha | ||
| 07.08. | BIODESIX INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Biodesix, Inc.: Biodesix Announces Second Quarter 2025 Results and Highlights | 178 | GlobeNewswire (Europe) | Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance... ► Artikel lesen | |
| 07.08. | BIODESIX INC - 8-K, Current Report | 2 | SEC Filings | ||
| 24.07. | Biodesix, Inc.: Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 | 1 | GlobeNewswire (USA) | ||
| 10.06. | Biodesix, Inc.: Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs | 1 | GlobeNewswire (USA) | ||
| 04.06. | Biodesix auf der 45. jährlichen William Blair Growth Stock Konferenz: Fokus auf Lungengesundheit | 3 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,97 | 0,00 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,290 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| DYNE THERAPEUTICS | 24,170 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| MAPLIGHT THERAPEUTICS | 18,050 | 0,00 % | MapLight Therapeutics Prices IPO Of 14.75 Mln Shares At $17.00/shr | WASHINGTON (dpa-AFX) - MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company focused on
improving the lives of patients suffering from debilitating central nervous
system... ► Artikel lesen | |
| NUVALENT | 97,95 | +4,88 % | Piper Sandler erhöht Kursziel für Nuvalent auf 128 US-Dollar wegen ALK-Potenzial | ||
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 186,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 58,53 | 0,00 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ZENAS BIOPHARMA | 31,500 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis | - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,470 | 0,00 % | Summit Therapeutics: A Risky Bet in the Biotech Arena? | ||
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,605 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| IMMUNOVANT | 21,420 | 0,00 % | Immunovant Inc.: Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 | ||
| VENTYX BIOSCIENCES | 6,460 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,210 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen |